What a run! Although it has already become a true tradition for Valneva, running the Vienna Business Run is exciting every year. 41 motivated Austrian colleagues🏃 joined 33.000 other runners in the 4.3 km run on the beautiful Danube Island last Friday. We were overwhelmed by the team spirit and the ambition of our runners. We congratulate them all and thank the organizers for making this event run so smoothly. See you again next year! #AdvancingVaccinesForBetterLives
Valneva
Recherche en biotechnologie
Saint-Herblain, Pays de la Loire 36 959 abonnés
Specialty vaccine company focused on prevention of infectious diseases with major unmet need, such as Lyme & chikungunya
À propos
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines, including the world’s first and only chikungunya vaccine, as well as certain third-party vaccines. Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the U.S. with approximately 700 employees.
- Site web
-
http://www.valneva.com
Lien externe pour Valneva
- Secteur
- Recherche en biotechnologie
- Taille de l’entreprise
- 501-1 000 employés
- Siège social
- Saint-Herblain, Pays de la Loire
- Type
- Société cotée en bourse
- Fondée en
- 2013
- Domaines
- vaccines
Lieux
Employés chez Valneva
Nouvelles
-
We are continuing with our #EmployeeSpotlight series – meet Jana! Jana is one of our Clinical Operations Managers here at Valneva. Her role is to collect clinical data that show the efficacy and safety of our vaccines, to support with registration of our products with the authorities. Thanks to our expert team members like Jana, we continue to successfully advance a broad range of vaccine candidates, supporting our bold mission to contribute to a world in which no one dies or suffers from a vaccine-preventable disease. Check out our interview with Jana to learn more about her role and why she enjoys working at Valneva. #AdvancingVaccinesForBetterLives
-
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate https://ow.ly/ZPBr50TcUug
-
-
What travelers should know about mosquito-borne diseases 🌍🦟 On September 6th, São Paulo will host its first-ever American football game. Brazil has the highest number of mosquito species in the world so here we share some facts on mosquito-borne diseases and practical tips for travelers to Brazil or anywhere in the world where there are mosquitoes. #AmericanFootball #Brazil2024 #MosquitoBorneDiseases #AdvancingVaccinesForBetterLives
The season opener for two American Football teams will be played in São Paulo, Brazil, on September 6. What fans traveling to the game may not know is that Brazil has the most mosquitoes in the world. Mosquitoes carry diseases like Chikungunya. Learn more from Valneva Chief Medical Officer, Dr. Juan Carlos Jaramillo. https://bit.ly/4e0QpSP
-
-
"I can track my drive to work in life sciences to one moment from my childhood, when I was around seven years old." Greig Rooney, Managing Director of Valneva Scotland, contracted malaria as a child while living in North Yemen. In honor of World Mosquito Day and to raise awareness about mosquito-borne diseases, he shares his story and the profound impact it has had on his life. Read more here - https://lnkd.in/egR8CgxD #WorldMosquitoDay #MosquitoBorneDiseases #AdvancingVaccinesForBetterLives
-
This World Mosquito Day, we’re raising awareness about the growing threat of mosquito-borne diseases. While there are over 3,000 mosquito species worldwide, just two species – Aedes aegypti and Aedes albopictus – are responsible for transmitting the most common diseases, including dengue, chikungunya, Zika, and yellow fever. Historically these mosquitos have historically inhabited tropical regions, but they are now expanding their reach due to climate change. Projections suggest that by the end of the century, as many as 8.4 billion people could be at risk of contracting mosquito-borne diseases, representing a substantial public health threat we must address. At Valneva, we remain committed to our bold mission: to contribute to a healthier and safer world in which no one dies or suffers from a vaccine-preventable disease. To learn more, read our blog here: https://rb.gy/mlkr8b #WorldMosquitoDay #Mosquitobornediseases #AdvancingVaccinesForBetterLives
-
Today is World Humanitarian Day. At Valneva, we recognize the important role of vaccines in humanitarian aid, serving as essential tools in reducing disease spread during conflicts and disasters. Global immunization efforts have saved an estimated 154 million lives over the last 50 years, providing protection even in the most challenging environments. However, according to UNICEF, 25 million children are still missing out on life-saving vaccines every year, placing them at risk of preventable diseases – with the poorest and most marginalized children being the most affected. As we mark this day, we recognize those who are at the forefront of global change and we unite in our commitment to ensuring equitable access to life-saving vaccines worldwide. Together, we can build a healthier and safer future for all. #WorldHumanitarianDay #AdvancingVaccinesForBetterLives
-
-
Valneva’s H1 2024 Results Conference Call begins at 3 pm CEST/9 am EDT Connect to the webcast: https://lnkd.in/dQF3MYsk
-
-
Peer-reviewed medical journal, The Lancet Infectious Diseases, just published Phase 3 antibody persistence results twenty-four months after vaccination with a single dose of Valneva’s chikungunya vaccine. Read more here: https://lnkd.in/dhZ2Caav
-